<?xml version='1.0' encoding='utf-8'?>
<document id="29193123"><sentence text="Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers."><entity charOffset="84-93" id="DDI-PubMed.29193123.s1.e0" text="Gefitinib" /></sentence><sentence text="Gefitinib is a selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase and is used for the treatment of non-small-cell lung cancer (NSCLC) with activating EGFR mutations"><entity charOffset="0-9" id="DDI-PubMed.29193123.s2.e0" text="Gefitinib" /><entity charOffset="78-86" id="DDI-PubMed.29193123.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.29193123.s2.e0" e2="DDI-PubMed.29193123.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29193123.s2.e0" e2="DDI-PubMed.29193123.s2.e1" /></sentence><sentence text=" Gefitinib is metabolized by CYP2D6 and CYP3A4"><entity charOffset="1-10" id="DDI-PubMed.29193123.s3.e0" text="Gefitinib" /></sentence><sentence text=" This analysis compared the systemic exposure of gefitinib after oral administration in CYP2D6 ultrarapid metabolizers (UM) vs extensive metabolizers (EM)"><entity charOffset="49-58" id="DDI-PubMed.29193123.s4.e0" text="gefitinib" /></sentence><sentence text=" Physiologically based pharmacokinetic (PBPK) modeling was conducted using a population-based simulator" /><sentence text=" The model was calibrated using itraconazole-gefitinib clinical drug-drug interaction data and validated with gefitinib data in CYP2D6 EM vs poor metabolizers (PM)"><entity charOffset="32-44" id="DDI-PubMed.29193123.s6.e0" text="itraconazole" /><entity charOffset="45-54" id="DDI-PubMed.29193123.s6.e1" text="gefitinib" /><pair ddi="false" e1="DDI-PubMed.29193123.s6.e0" e2="DDI-PubMed.29193123.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29193123.s6.e0" e2="DDI-PubMed.29193123.s6.e1" /></sentence><sentence text=" System components of the PBPK model were evaluated using published clinical metoprolol pharmacokinetic data in CYP2D6 UM, EM, and PM"><entity charOffset="77-87" id="DDI-PubMed.29193123.s7.e0" text="metoprolol" /></sentence><sentence text=" Our PBPK model predicted a gefitinib geometric least-squares mean area under the plasma concentration-time curve (AUC) from time 0 to 264 hours (AUC(0-264) ) ratio in the presence vs absence of itraconazole of 1"><entity charOffset="28-37" id="DDI-PubMed.29193123.s8.e0" text="gefitinib" /><entity charOffset="195-207" id="DDI-PubMed.29193123.s8.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.29193123.s8.e0" e2="DDI-PubMed.29193123.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29193123.s8.e0" e2="DDI-PubMed.29193123.s8.e1" /></sentence><sentence text="85, similar to the ratio of 1" /><sentence text="78 from clinical study data" /><sentence text=" Predicted and observed metoprolol geometric least-squares mean AUC(0-24) ratios in UM vs EM were also similar (0"><entity charOffset="24-34" id="DDI-PubMed.29193123.s11.e0" text="metoprolol" /></sentence><sentence text="46 and 0" /><sentence text="55, respectively), suggesting that system components related to CYP2D6 in the PBPK model were properly established" /><sentence text=" In addition, the PBPK model also captured gefitinib pharmacokinetic profiles in CYP2D6 polymorphic populations"><entity charOffset="43-52" id="DDI-PubMed.29193123.s14.e0" text="gefitinib" /></sentence><sentence text=" The final PBPK model predicted a decrease in gefitinib AUC of âˆ¼39% in CYP2D6 UM vs EM" /><sentence text=" Such changes in exposure will have limited impact as the reduced exposure is still above gefitinib's in vitro IC90 for EGFR activating mutations in NSCLC patients" /><sentence text="" /></document>